KR102041154B1 - 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물 - Google Patents

칼슘 감지 수용체 조절자로서의 치환 크로만 화합물 Download PDF

Info

Publication number
KR102041154B1
KR102041154B1 KR1020147025242A KR20147025242A KR102041154B1 KR 102041154 B1 KR102041154 B1 KR 102041154B1 KR 1020147025242 A KR1020147025242 A KR 1020147025242A KR 20147025242 A KR20147025242 A KR 20147025242A KR 102041154 B1 KR102041154 B1 KR 102041154B1
Authority
KR
South Korea
Prior art keywords
methyl
ethyl
amino
chroman
naphthalen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147025242A
Other languages
English (en)
Korean (ko)
Other versions
KR20140135731A (ko
Inventor
마노즈쿠마르 람프라사드 슈크라
안쿠쉬 간가람 사르데
라제시쿠마르 마간랄 로리야
비풀 딜립 파치푸테
나브나트 바지라오 왈케
탈하 후사인 칸
산지브 아난트 쿨카르니
벤카다 피. 팔레
라젠더 쿠마르 캄보즈
Original Assignee
루핀 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루핀 리미티드 filed Critical 루핀 리미티드
Publication of KR20140135731A publication Critical patent/KR20140135731A/ko
Application granted granted Critical
Publication of KR102041154B1 publication Critical patent/KR102041154B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
KR1020147025242A 2012-02-24 2013-02-22 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물 Active KR102041154B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN178/KOL/2012 2012-02-24
IN1030KO2012 2012-09-07
IN1030/KOL/2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (2)

Publication Number Publication Date
KR20140135731A KR20140135731A (ko) 2014-11-26
KR102041154B1 true KR102041154B1 (ko) 2019-11-07

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147025242A Active KR102041154B1 (ko) 2012-02-24 2013-02-22 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물

Country Status (44)

Country Link
US (3) US9163001B2 (enExample)
EP (1) EP2817299B1 (enExample)
JP (1) JP6114316B2 (enExample)
KR (1) KR102041154B1 (enExample)
CN (1) CN104350047B (enExample)
AP (1) AP2014007919A0 (enExample)
AR (1) AR090135A1 (enExample)
AU (1) AU2013223715B2 (enExample)
BR (1) BR112014021133B1 (enExample)
CA (1) CA2864332C (enExample)
CL (1) CL2014002218A1 (enExample)
CO (1) CO7160018A2 (enExample)
CR (1) CR20140424A (enExample)
CU (1) CU24325B1 (enExample)
CY (1) CY1122017T1 (enExample)
DK (1) DK2817299T3 (enExample)
DO (1) DOP2014000193A (enExample)
EA (1) EA026940B9 (enExample)
ES (1) ES2743492T3 (enExample)
GE (2) GEAP201813579A (enExample)
GT (1) GT201400179A (enExample)
HR (1) HRP20191606T1 (enExample)
HU (1) HUE046172T2 (enExample)
IL (1) IL234252A (enExample)
IN (1) IN2014MN01672A (enExample)
LT (1) LT2817299T (enExample)
MA (1) MA35937B1 (enExample)
MX (1) MX355670B (enExample)
MY (1) MY171374A (enExample)
NI (1) NI201400094A (enExample)
NZ (1) NZ628627A (enExample)
PE (1) PE20142281A1 (enExample)
PH (1) PH12014501891B1 (enExample)
PL (1) PL2817299T3 (enExample)
PT (1) PT2817299T (enExample)
RS (1) RS59172B1 (enExample)
SG (1) SG11201405117SA (enExample)
SI (1) SI2817299T1 (enExample)
SM (1) SMT201900506T1 (enExample)
TN (1) TN2014000352A1 (enExample)
TW (1) TWI617549B (enExample)
UA (1) UA112679C2 (enExample)
WO (1) WO2013124828A1 (enExample)
ZA (1) ZA201405990B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20191606T1 (hr) * 2012-02-24 2019-12-13 Lupin Ltd Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij
CA2882039A1 (en) * 2012-08-27 2014-03-06 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
CA2920818A1 (en) 2013-08-28 2015-03-05 Lupin Limited Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
JP7764372B2 (ja) 2019-11-19 2025-11-05 ルピン・リミテッド クロマン化合物を調製する方法
CA3166210A1 (en) * 2019-12-27 2021-07-01 Lupin Limited Pharmaceutical composition of casr modulators and methods and uses thereof
MX2022008805A (es) 2020-01-17 2022-08-11 Lupin Ltd Metodos, procesos e intermedios para preparar compuestos cromanos.
WO2025255092A1 (en) * 2024-06-03 2025-12-11 Artax Biopharma Inc. Combination of a chromene derivative tcr inhibitor and a tyk2 inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012127388A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0020018B1 (en) * 1979-05-19 1983-06-01 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. CaSRアンタゴニスト
CA2608957C (en) 2005-05-19 2013-12-10 Astellas Pharma Inc. Pyrrolidine derivative or salt thereof
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド[4,3−d]ピリミジン−4(3H)−オン誘導体
CA2672956C (en) * 2006-10-26 2015-02-10 Amgen Inc. Calcium receptor modulating agents
WO2008059854A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivatives or salts thereof
WO2009051718A2 (en) * 2007-10-15 2009-04-23 Amgen Inc. Calcium receptor modulating agents
US9487494B2 (en) 2007-11-23 2016-11-08 Leo Pharma A/S Cyclic hydrocarbon compounds for the treatment of diseases
WO2010038895A1 (ja) 2008-10-03 2010-04-08 味の素株式会社 CaSRアゴニスト
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
EP2435404A1 (en) 2009-05-27 2012-04-04 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
EP2643298A1 (en) 2010-11-26 2013-10-02 Leo Pharma A/S Substituted cyclopentyl - azines as casr- active compounds
WO2012069419A1 (en) 2010-11-26 2012-05-31 Leo Pharma A/S Calcium-sensing receptor-active compounds
CA2828415A1 (en) 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
HRP20191606T1 (hr) * 2012-02-24 2019-12-13 Lupin Ltd Supstituirani spojevi kromana kao modulatori receptora osjetljivog na kalcij

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012127388A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioogranic & Medicinal Chemistry Letters, 20(24) pp.7483-7487(2010)
Expert Opin. Ther. Patents, 21(5), pp.681-698(2011)

Also Published As

Publication number Publication date
KR20140135731A (ko) 2014-11-26
DOP2014000193A (es) 2017-01-15
JP2015508097A (ja) 2015-03-16
GEP20186911B (en) 2018-10-25
HRP20191606T1 (hr) 2019-12-13
ZA201405990B (en) 2015-11-25
DK2817299T3 (da) 2019-09-16
TN2014000352A1 (en) 2015-12-21
AU2013223715A1 (en) 2014-08-28
SI2817299T1 (sl) 2019-10-30
US20170209410A1 (en) 2017-07-27
TW201336831A (zh) 2013-09-16
EP2817299A1 (en) 2014-12-31
IL234252A (en) 2017-02-28
CU20140103A7 (es) 2015-01-29
CY1122017T1 (el) 2020-10-14
CU24325B1 (es) 2018-03-13
UA112679C2 (uk) 2016-10-10
NI201400094A (es) 2015-03-27
BR112014021133B1 (pt) 2022-06-28
GT201400179A (es) 2016-03-01
TWI617549B (zh) 2018-03-11
MX355670B (es) 2018-04-25
US9163001B2 (en) 2015-10-20
MX2014010139A (es) 2015-09-04
PH12014501891B1 (en) 2021-05-05
GEAP201813579A (en) 2018-06-25
IN2014MN01672A (enExample) 2015-05-29
PH12014501891A1 (en) 2015-02-09
CA2864332A1 (en) 2013-08-29
AR090135A1 (es) 2014-10-22
AU2013223715B2 (en) 2017-09-14
US9598391B2 (en) 2017-03-21
BR112014021133A2 (pt) 2018-09-11
CR20140424A (es) 2015-01-13
EA026940B1 (ru) 2017-06-30
US20150368222A1 (en) 2015-12-24
LT2817299T (lt) 2019-09-25
JP6114316B2 (ja) 2017-04-12
ES2743492T3 (es) 2020-02-19
MY171374A (en) 2019-10-10
SMT201900506T1 (it) 2019-11-13
EP2817299B1 (en) 2019-06-12
EA201491582A1 (ru) 2014-12-30
CO7160018A2 (es) 2015-01-15
CN104350047B (zh) 2017-05-24
CL2014002218A1 (es) 2015-03-06
HUE046172T2 (hu) 2020-02-28
US9987249B2 (en) 2018-06-05
CA2864332C (en) 2020-08-25
PT2817299T (pt) 2019-09-23
HK1205117A1 (en) 2015-12-11
MA35937B1 (fr) 2014-12-01
US20150038546A1 (en) 2015-02-05
NZ628627A (en) 2017-02-24
PE20142281A1 (es) 2015-01-16
WO2013124828A1 (en) 2013-08-29
EA026940B9 (ru) 2017-11-30
AP2014007919A0 (en) 2014-09-30
SG11201405117SA (en) 2014-09-26
CN104350047A (zh) 2015-02-11
PL2817299T3 (pl) 2019-12-31
RS59172B1 (sr) 2019-10-31

Similar Documents

Publication Publication Date Title
KR102041154B1 (ko) 칼슘 감지 수용체 조절자로서의 치환 크로만 화합물
WO2012127388A1 (en) Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
WO2003014113A1 (en) Novel benzopyran compounds and process for their preparation and use
WO2015162538A1 (en) Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
RU2722441C2 (ru) Замещённые индольные соединения в качестве понижающих регуляторов рецепторов эстрогена
WO2013136288A1 (en) Substituted 3,4-dihydro-2h-benzo[b] [1,4]oxazine compounds as calcium sensing receptor modulators
CN104583177B (zh) 作为钙敏感受体调节剂的芳基烷基胺化合物
ES2348838T3 (es) Compuestos de cicloalquilideno como moduladores slectivos del receptor de estrã“genos.
WO2015028938A1 (en) Substituted naphthalene compounds as calcium sensing receptor modulators
HK1205117B (en) Substituted chroman compounds as calcium sensing receptor modulators
WO2017037616A1 (en) Arylalkylamine compounds as calcium sensing receptor modulators
NZ736165A (en) Compositions for the treatment of kidney and/or liver disease
JP2008543741A (ja) 新規な化合物
WO2000051959A1 (fr) Derives fluores de chalcone ou leurs sels, et medicaments contenant ces derives comme principe actif
OA17086A (en) Substituted chroman compounds as calcium sensing receptor modulators.
HK1206329B (en) Phenol derivative, method of preparing same, and pharmaceutical application of same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140905

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20161115

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171201

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20180409

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190607

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191023

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191031

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191101

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220923

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230925

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee